MediWound (NASDAQ:MDWD) Stock Crosses Above Fifty Day Moving Average - Here's Why

Key Points

• MediWound Ltd. shares crossed above their fifty-day moving average, reaching a high of $17.90, while closing at $17.54 with a trading volume of 47,910 shares.
• Recent analyst ratings for MediWound varied, with Zacks downgrading the stock to "hold", while the consensus rating remains a "Moderate Buy" with an average price target of $32.25.
• The company reported a loss of $1.23 EPS for the last quarter, missing estimates, while revenue slightly exceeded expectations at $5.71 million.

Shares of MediWound Ltd. (NASDAQ:MDWD - Get Free Report) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $17.65 and traded as high as $17.90. MediWound shares last traded at $17.54, with a volume of 47,910 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on MDWD shares. Zacks Research downgraded MediWound from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Wall Street Zen downgraded MediWound from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of MediWound in a research note on Saturday, September 27th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $32.25.

MediWound Stock Performance

The firm has a market cap of $194.52 million, a price-to-earnings ratio of -6.64 and a beta of 0.27. The business has a fifty day simple moving average of $17.65 and a 200-day simple moving average of $18.46.

MediWound (NASDAQ:MDWD - Get Free Report) last announced its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.68). The company had revenue of $5.71 million for the quarter, compared to analyst estimates of $5.68 million. MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%. On average, equities analysts anticipate that MediWound Ltd. will post -2.66 earnings per share for the current year.

Institutional Trading of MediWound

Large investors have recently bought and sold shares of the business. GAMMA Investing LLC raised its holdings in shares of MediWound by 1,507.1% during the first quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 1,703 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 649 shares during the last quarter. Corebridge Financial Inc. grew its holdings in shares of MediWound by 17.1% during the first quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 665 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock valued at $85,000 after buying an additional 999 shares during the last quarter. Finally, Deutsche Bank AG grew its holdings in shares of MediWound by 2,255.2% during the first quarter. Deutsche Bank AG now owns 6,312 shares of the biopharmaceutical company's stock valued at $98,000 after buying an additional 6,044 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.